GENMAB A/S/S (OTCMKTS:GMXAY) Shares Up 4% – What’s Next?

Shares of GENMAB A/S/S (OTCMKTS:GMXAY) were up 4% during mid-day trading on Wednesday. The company traded as high as $55.91 and last traded at $55.80. Approximately 5,137,139 shares were traded during trading, an increase of 10,480% from the average session volume of 48,553 shares. The stock had previously closed at $53.63.

GENMAB A/S/S Stock Performance

The stock’s 50-day moving average price is $40.18 and its 200-day moving average price is $31.35.

Institutional Trading of GENMAB A/S/S

An institutional investor recently bought a new position in GENMAB A/S/S stock. Madison Asset Management LLC bought a new position in shares of GENMAB A/S/S (OTCMKTS:GMXAY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing, and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to develop therapies designed to engage the immune system and target disease-related mechanisms. Genmab’s marketed and partnered products include DARZALEX (daratumumab) for certain blood cancers, EPKINLY (epcoritamab) for certain types of B-cell lymphoma, and Tivdak (tisotumab vedotin) for cervical cancer.